Montelukast in pediatric asthma management

Area of Science:

• Pharmacology
• Respiratory Medicine
• Pediatric Pulmonology

Background:

• Leukotriene modifiers are the first mediator-specific asthma therapies.
• Montelukast is the only leukotriene receptor antagonist approved for pediatric use.
• Leukotrienes are potent bronchoconstrictors, and montelukast blocks their receptors.

Purpose of the Study:

• To review the efficacy and safety of montelukast in asthma management.
• To evaluate montelukast's role in different asthma severities and patient populations.
• To compare montelukast with other asthma medications like inhaled corticosteroids and long-acting beta agonists.

Main Methods:

• Systematic review of existing literature on montelukast in asthma.
• Analysis of clinical trial data comparing montelukast to placebo, inhaled corticosteroids, and long-acting beta agonists.
• Inclusion of studies on pediatric patients, exercise-induced asthma, and aspirin-sensitive asthma.

Main Results:

• Montelukast demonstrates clinical efficacy in controlling daytime asthma symptoms, reducing the need for rescue drugs, and improving FEV1 compared to placebo.
• Studies show montelukast reduces airway inflammation, evidenced by decreased fractional exhaled nitric oxide.
• Montelukast is not superior to low-dose inhaled corticosteroids in children and is less efficacious and cost-effective than long-acting beta agonists as add-on therapy for moderate to severe persistent asthma.

Conclusions:

• Montelukast is a viable alternative for mild persistent asthma monotherapy when inhaled corticosteroids are not feasible.
• It serves as an alternative add-on therapy to inhaled corticosteroids for moderate to severe persistent asthma.
• Montelukast is beneficial for exercise-induced and aspirin-sensitive asthma, with rapid onset of action and improved patient compliance due to once-daily oral administration.